Syndax Pharma Reports Increased Fourth Quarter Loss

Syndax Pharma reveals a significant loss in its fourth quarter. The company's earnings fell short of analysts' expectations, which could negatively impact its stock price.

Date: 03-03-2025

AI Rating: 4

Syndax Pharma's Fourth Quarter Performance

Syndax Pharma (SNDX) reported a loss for its fourth quarter which increased compared to the same period last year, indicating a negative trend for the company. The earnings reported were -$94.17 million or -$1.10 per share, compared to -$72.47 million or -$1.00 per share from the previous year. This shows a deterioration in profitability.

The report explicitly notes that Syndax missed the earnings consensus from analysts, who had anticipated a loss of only -$0.23 per share, which is a significant miss against the expected performance.

Given this information, we can analyze the following metrics:

Earnings Per Share (EPS): The EPS for the quarter is reported at -$1.10, worse than the previous year's -$1.00, indicating increased losses.
Net Income: The net income has worsened, going from -$72.47 million to -$94.17 million year-over-year, showing a declining financial health.

This performance could lead to potential negative sentiments among investors and could drive the stock price down as expectations were not met.

Stocks: SNDX